A patient developed lymphadenopathy while receiving diphenylhydantoin therapy that histologically resembled malignant lymphoma. Adenopathy regressed when diphenylhydantoin was discontinued but subsequently recurred as a fatal, malignant lymphoma. Previous reports of hydantoin-induced lymphadenopathy were reviewed and classified. It was found that no consistent clinical or histologic criteria existed to differentiate benign from malignant lymphoid reactions.
No takes yet. Share an insight, caveat, or question.
Richard A. Gams (1968) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: